Alpha-2C Adrenergic Receptor Protein

Alpha-2C Adrenergic Receptor (ADRA2C)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="text-align:center;">Alpha-2C Adrenergic Receptor</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Alpha-2C adrenergic receptor</td></tr>
<tr><td><strong>Gene</strong></td><td>ADRA2C</td></tr>
<tr><td><strong>UniProt</strong></td><td>[P08913](https://www.uniprot.org/uniprotkb/P08913)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>G-protein coupled receptor (GPCR)</td></tr>
<tr><td><strong>Localization</strong></td><td>Cell membrane; presynaptic terminals</td></tr>
<tr><td><strong>Major Pathway</strong></td><td>[Adrenergic Signaling](/mechanisms/adrenergic-signaling)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

ADRA2C encodes the alpha-2C adrenergic receptor (α2C-AR), one of three alpha-2 adrenergic receptor subtypes (α2A, α2B, α2C) that belong to the G protein-coupled receptor (GPCR) superfamily. The α2C-AR is distinguished by its unique anatomical distribution, particularly in the central nervous system, and its role in modulating neurotransmitter release under basal and stressed conditions[@tansey2002][@culver2001].

Alpha-2C Adrenergic Receptor (ADRA2C)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="text-align:center;">Alpha-2C Adrenergic Receptor</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Alpha-2C adrenergic receptor</td></tr>
<tr><td><strong>Gene</strong></td><td>ADRA2C</td></tr>
<tr><td><strong>UniProt</strong></td><td>[P08913](https://www.uniprot.org/uniprotkb/P08913)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>G-protein coupled receptor (GPCR)</td></tr>
<tr><td><strong>Localization</strong></td><td>Cell membrane; presynaptic terminals</td></tr>
<tr><td><strong>Major Pathway</strong></td><td>[Adrenergic Signaling](/mechanisms/adrenergic-signaling)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

ADRA2C encodes the alpha-2C adrenergic receptor (α2C-AR), one of three alpha-2 adrenergic receptor subtypes (α2A, α2B, α2C) that belong to the G protein-coupled receptor (GPCR) superfamily. The α2C-AR is distinguished by its unique anatomical distribution, particularly in the central nervous system, and its role in modulating neurotransmitter release under basal and stressed conditions[@tansey2002][@culver2001].

Unlike the α2A and α2B subtypes, which are widely expressed throughout the brain and peripheral tissues, the α2C-AR exhibits a more restricted distribution with particularly high expression in regions involved in motor control and autonomic function. This distribution pattern has made it a focus of interest in neurodegenerative disease research[@schmitt2003][@rommelfanger2007].

Structure and Pharmacology

Receptor Structure

The ADRA2C receptor is a 461 amino acid GPCR with characteristic seven-transmembrane domain architecture. It shares structural features with other alpha-2 adrenergic receptors but exhibits distinct pharmacological properties:

• N-terminal extracellular region: Contains glycosylation sites
• Transmembrane domains (TM1-TM7): Seven alpha-helices spanning the membrane
• Intracellular loops: Couple to G proteins
• C-terminal intracellular domain: Contains phosphorylation sites for desensitization

Ligand Binding

Alpha-2 adrenergic receptors are activated by endogenous catecholamines including norepinephrine (noradrenaline) and epinephrine (adrenaline), as well as by synthetic agonists such as clonidine and dexmedetomidine. The α2C-AR has distinct pharmacological profiles:

• Agonists: Clonidine, dexmedetomidine, brimonidine, guanfacine
• Antagonists: Idazoxan, yohimbine, atipamezole

Tissue Distribution

Central Nervous System

The α2C-AR has a distinctive distribution pattern in the brain[@culver2001]:

• Basal ganglia: High expression in striatum and substantia nigra
• Hippocampus: Moderate expression in CA regions
• Cortex: Layer-specific expression
• Locus coeruleus: Associated with noradrenergic neurons
• Spinal cord: Dorsal horn and autonomic regions
• Cerebellum: Purkinje cell layer

Peripheral Tissues

Lower expression in peripheral organs:

• Platelets: Modulates platelet aggregation
• Adipose tissue: Regulates lipolysis
• Pancreas: Modulates insulin secretion
• Heart: Cardiac effects under stress

Physiological Functions

Presynaptic Modulation

The α2C-AR plays a critical role in presynaptic regulation of neurotransmitter release:

• Norepinephrine release: Autoreceptor-mediated inhibition
• Dopamine modulation: Influences dopaminergic signaling
• Serotonin modulation: Cross-talk with serotonergic systems
• Glutamate modulation: Regulates excitatory neurotransmission
• GABA modulation: Effects on inhibitory neurotransmission

Stress Response

The receptor is Particularly important in modulating stress responses:

• HPA axis modulation: Affects hypothalamic-pituitary-adrenal (HPA) axis activity
• Cortisol regulation: Modulates glucocorticoid release
• Stress-induced behaviors: Alters anxiety and fear responses
• Thermoregulation: Involved in cold stress responses

Glial Cell Regulation

ADRA2C is expressed in glial cells and modulates their function[@gibson2016]:

• Microglial activation: Regulates inflammatory responses
• Astrocyte function: Modulates astrocytic signaling
• Oligodendrocyte support: May influence myelination

Evidence in Neurodegenerative Disease

Alzheimer's Disease

The noradrenergic system is prominently affected in Alzheimer's disease, and ADRA2C has been implicated in disease pathogenesis[@manaye2017][@espay2014]:

• Noradrenergic degeneration: Loss of locus coeruleus neurons in AD
• Receptor upregulation: compensatory changes in α2-AR expression
• Neuroinflammation: α2C-AR modulates microglial activation
• Memory and attention: Noradrenergic modulation of cognition
• Therapeutic potential: Clonidine and other α2-agonists have been explored

Parkinson's Disease

ADRA2C has emerged as particularly relevant in Parkinson's disease[@rommelfanger2007][@henning2019][@chiang2019]:

• Norepinephrine deficiency: Marked loss of noradrenergic neurons
• α-Synuclein interaction: Evidence for cross-talk with α-synuclein pathology
• Neuroinflammation: α2C-AR modulation of microglial activation
• Motor dysfunction: Noradrenergic contributions to motor symptoms
• Non-motor symptoms: Autonomic dysfunction, depression, fatigue

Other Neurodegenerative Disorders

• Amyotrophic Lateral Sclerosis (ALS): Altered adrenergic signaling
• Huntington's Disease: Noradrenergic system involvement
• Multiple System Atrophy: Autonomic dysfunction
• Frontotemporal Dementia: Noradrenergic changes

Therapeutic Targeting

Why ADRA2C is Attractive

The α2C-AR represents a compelling therapeutic target for several reasons[@vasudevan2001][@espay2014]:

• Neuroprotective potential: Agonists can reduce excitotoxicity
• Anti-inflammatory effects: Modulates microglial activation
• Cognitive enhancement: Noradrenergic modulation of attention and memory
• Disease modification: Evidence for interaction with protein aggregation

Current Therapeutic Approaches

Several strategies are being explored:

Clinical Considerations

• Blood pressure effects: Hypotension with systemic agonists
• Sedation: Central nervous system depression
• Rebound hypertension: Upon withdrawal
• Timing: Effects may vary with disease stage

Biomarkers and Diagnostics

Clinical Applications

• Receptor imaging: PET ligands under development
• CSF biomarkers: Correlates with disease progression
• Functional assessments: Blood pressure responses to agonists

Therapeutic Monitoring

• Norepinephrine levels: Plasma and CSF measurements
• Blood pressure: Agonist effects on blood pressure
• Cognitive testing: Attention and memory assessments

Interactions with Other Systems

Dopaminergic System

The noradrenergic and dopaminergic systems are closely linked:

• Substantia nigra: Both systems project to striatum
• Ventral tegmental area: Cross-talk between systems
• Motor control: Additive effects on movement

Serotonergic System

• Raphe nuclei: Noradrenergic modulation
• Mood regulation: Both systems affect depression
• Sleep-wake cycle: Shared regulatory functions

Cholinergic System

• Basal forebrain: Noradrenergic modulation of cholinergic neurons
• Memory: Interactions in hippocampal circuitry
• Attention: Coordinated modulation

Research Challenges

Knowledge Gaps

• Cell-type specificity: Effects on specific neuronal populations
• Disease staging: Optimal timing for intervention
• Biomarkers: Lack of validated biomarkers
• Clinical translation: Bridging preclinical and clinical findings

Future Directions

• Selective ligands: Development of subtype-selective compounds
• Gene therapy: AAV-based approaches
• Combination therapy: With disease-modifying agents
• Biomarker development: Patient selection and monitoring

See Also

• [Norepinephrine System](/mechanisms/norepinephrine-system)
• [Alpha-2 Adrenergic Receptors](/mechanisms/alpha-2-adrenergic-receptors)
• [Adrenergic Signaling](/mechanisms/adrenergic-signaling)
• [Microglial Activation](/mechanisms/microglial-activation)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/proteins/alpha-synuclein)

References

External Links

• [UniProt: ADRA2C](https://www.uniprot.org/uniprotkb/P08913)
• [NCBI Gene: ADRA2C](https://www.ncbi.nlm.nih.gov/gene/151)
• [AlphaFold Structure](https://alphafold.ebi.ac.uk/entry/P08913)
• [IUPHAR Database: ADRA2C](https://www.guidetopharmacology.org/targets/36)